| Dr Andrew Paul Pecora, DO | |
|
73 N Maple Ave Ste B, Marlton, NJ 08053-1782 | |
| (856) 596-0558 | |
| (856) 596-4043 |
| Full Name | Dr Andrew Paul Pecora |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 73 N Maple Ave Ste B, Marlton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376637553 | NPI | - | NPPES |
| 6061001 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25MB05694000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc | Cherry hill, NJ | Home health agency |
| Serenity Hospice Care | Hamilton, NJ | Hospice |
| Samaritan Healthcare And Hospice | Marlton, NJ | Hospice |
| Baptist Home Of South Jersey | Riverton, NJ | Nursing home |
| Atrium Post Acute Care Of Woodbury | Woodbury, NJ | Nursing home |
| Mystic Meadows Rehab & Nursing Center | Little egg harbor tw, NJ | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Patient Care Medical Group Pc | 8022413459 | 15 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Entity Name | Inspira Health Network Urgent Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255613329 PECOS PAC ID: 2769657659 Enrollment ID: O20111205000169 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Entity Name | Jersey Irish Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144575739 PECOS PAC ID: 0941451215 Enrollment ID: O20121114000210 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Entity Name | Inspira Sj Urgent Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619320991 PECOS PAC ID: 0749566958 Enrollment ID: O20170424000682 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Entity Name | Patient Care Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891362364 PECOS PAC ID: 8022413459 Enrollment ID: O20210824001982 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Entity Name | Patient Care Specialty Group Pc |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1477213106 PECOS PAC ID: 3678951423 Enrollment ID: O20220607000951 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Paul Pecora, DO 73 N Maple Ave Ste B, Marlton, NJ 08053-1782 Ph: (856) 596-0558 | Dr Andrew Paul Pecora, DO 73 N Maple Ave Ste B, Marlton, NJ 08053-1782 Ph: (856) 596-0558 |
News Archive
Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen's Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.
A new large scale study has focussed on faulty BRCA genes and their linkage to breast and ovarian cancer. The research could help doctors counsel and advise their patients in a more definitive way in terms of treatment as well as lifestyle changes that could minimize cancer risk.
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
› Verified 9 days ago
Dr. Michael John Voyack, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Lincoln Dr W Ste F, Marlton, NJ 08053 Phone: 856-810-1800 Fax: 856-810-1879 | |
Dr. Sham Rustom Bajina, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 765 Route 70 East, Cfg Health Systems Llc Bldg A Suite 101, Marlton, NJ 08053 Phone: 856-983-3900 Fax: 856-810-0169 | |
Elizabeth Levinson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 534 Lippincott Dr, Marlton, NJ 08053 Phone: 856-985-7373 Fax: 856-985-9611 | |
Dr. Philip Getson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Brick Rd, Suite 206, Marlton, NJ 08053 Phone: 856-983-7246 Fax: 856-983-0908 | |
Mitesh Patel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 999 Route 73 N Ste 401, Marlton, NJ 08053 Phone: 800-321-9999 Fax: 267-479-1321 | |
Catharine C Mayer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Route 73 S Ste 303, Marlton, NJ 08053 Phone: 856-596-0555 | |
Dr. Eric Robert Requa, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Route 73 N Lowr Level, Marlton, NJ 08053 Phone: 844-908-5483 Fax: 856-355-7106 |